Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen

Clinical Microbiology and Infection

Volumn 24, Issue 4, 2018, Pages 429.e1-429.e5

  Werth, B J ^a   Jain, R ^a   Hahn, A ^b   Cummings, L ^a   Weaver, T ^a   Waalkes, A ^a   Sengupta, D ^a   Salipante, S J ^a   Rakita, R M ^b   Butler Wu, S M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CLABSI; Cross resistance; Dalbavancin; Glycopeptide resistance; Lipoglycopeptide

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; NAFCILLIN; TELAVANCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; TEICOPLANIN;

ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD CULTURE; BROTH DILUTION; CASE REPORT; CATHETER INFECTION; CLINICAL ARTICLE; CROSS RESISTANCE; HUMAN; IN VITRO SELECTION; IN VITRO STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; URINE CULTURE; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; WHOLE GENOME SEQUENCING; ANALOGS AND DERIVATIVES; BLOOD; DNA MUTATIONAL ANALYSIS; DRUG EFFECT; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; SEPSIS; STAPHYLOCOCCUS INFECTION; URINE; VIRUS CULTURE;

ADULT; ANTI-BACTERIAL AGENTS; BLOOD; CATHETER-RELATED INFECTIONS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; SEPSIS; SERIAL PASSAGE; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; URINE; VANCOMYCIN; WHOLE GENOME SEQUENCING;

EID: 85037048097     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2017.07.028     Document Type: Article

References (34)

1. Malabarba, A., Goldstein, B.P., Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 55:Suppl 2 (2005), ii15–ii20.
2. Biedenbach, D.J., Bell, J.M., Sader, H.S., Turnidge, J.D., Jones, R.N., Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother 53:3 (2009), 1260–1263.
3. Dalvance™ Package Insert, 2016, DurataTherapeutics U.S. Limited, Parsippany, NJ, USA.
4. Zhanel, G.G., Calic, D., Schweizer, F., Zelenitsky, S., Adam, H., Lagacé-Wiens, P.R., et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70:7 (2010), 859–886.
5. Dunne, M.W., Puttagunta, S., Giordano, P., Krievins, D., Zelasky, M., Baldassarre, J., A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis 62:5 (2016), 545–551.
6. Jones, R.N., Farrell, D.J., Flamm, R.K., Sader, H.S., Dunne, M.W., Mendes, R.E., Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagn Microbiol Infect Dis 82:1 (2015), 73–77.
7. Clinical and Laboratory Standards Institute, M07–A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard- tenth edition. 2015, CLSI, Wayne, PA, USA.
8. Ortwine, J.K., Werth, B.J., Sakoulas, G., Rybak, M.J., Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the “seesaw effect”: taking advantage of the back door left open?. Drug Resist Updat 16:3–5 (2013), 73–79.
9. Wootton, M., Howe, R.A., Hillman, R., Walsh, T.R., Bennett, P.M., MacGowan, A.P., A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47:4 (2001), 399–403.
10. Shopsin, B., Gomez, M., Montgomery, S.O., Smith, D.H., Waddington, M., Dodge, D.E., et al. Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J Clin Microbiol 37:11 (1999), 3556–3563.
11. Harmsen, D., Witte, W., Rothgänger, J., Claus, H., Turnwald, D., Vogel, U., Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 41:12 (2003), 5442–5448.
12. Woodward, J.F., Sengupta, D.J., Cookson, B.T., Park, J.O., Dellinger, E.P., Disseminated community-acquired USA300 methicillin-resistant Staphylococcus aureus pyomyositis and septic pulmonary emboli in an immunocompetent adult. Surg Infect (Larchmt) 11:1 (2010), 59–63.
13. Sabat, A., Krzyszton-Russjan, J., Strzalka, W., Filipek, R., Kosowska, K., Hryniewicz, W., et al. New method for typing Staphylococcus aureus strains: multiple-locus variable-number tandem repeat analysis of polymorphism and genetic relationships of clinical isolates. J Clin Microbiol 41:4 (2003), 1801–1804.
14. Salipante, S.J., SenGupta, D.J., Cummings, L.A., Land, T.A., Hoogestraat, D.R., Cookson, B.T., Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology. J Clin Microbiol 53:4 (2015), 1072–1079.
15. Cingolani, P., Platts, A., Wang le, L., Coon, M., Nguyen, T., Wang, L., et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6:2 (2012), 80–92.
16. Vidaillac, C., Gardete, S., Tewhey, R., Sakoulas, G., Kaatz, G.W., Rose, W.E., et al. Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus. J Infect Dis 208:1 (2013), 67–74.
17. Mwangi, M.M., Wu, S.W., Zhou, Y., Sieradzki, K., de Lencastre, H., Richardson, P., et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 104:22 (2007), 9451–9456.
18. Snitkin, E.S., Zelazny, A.M., Thomas, P.J., Stock, F., NISC Comparative Sequencing Program Group, Henderson, D.K., et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med, 4(148), 2012, 148ra116.
19. Mathers, A.J., Stoesser, N., Sheppard, A.E., Pankhurst, L., Giess, A., Yeh, A.J., et al. Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae at a single institution: insights into endemicity from whole-genome sequencing. Antimicrob Agents Chemother 59:3 (2015), 1656–1663.
20. Gardete, S., Kim, C., Hartmann, B.M., Mwangi, M., Roux, C.M., Dunman, P.M., et al. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog, 8(2), 2012, e1002505.
21. Fujimura, T., Murakami, K., Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion. Antimicrob Agents Chemother 52:2 (2008), 643–647.
22. Song, Y., Lunde, C.S., Benton, B.M., Wilkinson, B.J., Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant. Microb Drug Resist 19:4 (2013), 247–255.
23. Werth, B.J., Steed, M.E., Kaatz, G.W., Rybak, M.J., Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the “seesaw effect”. Antimicrob Agents Chemother 57:6 (2013), 2664–2668.
24. Sieradzki, K., Leski, T., Dick, J., Borio, L., Tomasz, A., Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol 41:4 (2003), 1687–1693.
25. Jones, R.N., Rhomberg, P.R., Mendes, R.E., Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014). Diagn Microbiol Infect Dis 86:2 (2016), 249–251.
26. Citron, D.M., Tyrrell, K.L., Goldstein, E.J., Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. Diagn Microbiol Infect Dis 79:4 (2014), 438–440.
27. Howden, B.P., Davies, J.K., Johnson, P.D., Stinear, T.P., Grayson, M.L., Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23:1 (2010), 99–139.
28. Durata Therapeutics International, Dalbavancin for Injection. NDA 021–883. 2014 (Accessed 5/21/2016) http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM390793.pdf.
29. Drlica, K., Zhao, X., Mutant selection window hypothesis updated. Clin Infect Dis 44:5 (2007), 681–688.
30. Leighton, A., Gottlieb, A.B., Dorr, M.B., Jabes, D., Mosconi, G., VanSaders, C., et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 48:3 (2004), 940–945.
31. Goldstein, B.P., Draghi, D.C., Sheehan, D.J., Hogan, P., Sahm, D.F., Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 51:4 (2007), 1150–1154.
32. Lopez, S., Hackbarth, C., Romano, G., Trias, J., Jabes, D., Goldstein, B.P., In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother, 55(Suppl 2), 2005 ii21–i24.
33. Dowell, J.A., Goldstein, B.P., Buckwalter, M., Stogniew, M., Damle, B., Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol 48:9 (2008), 1063–1068.
34. Lepak, A., Marchillo, K., VanHecker, J., Andes, D., Impact of glycopeptide resistance in Staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target. Antimicrob Agents Chemother 59:12 (2015), 7833–7836.